Expression of microRNA‑214 and galectin‑3 in peripheral blood of patients with chronic heart failure and its clinical significance

Han, Ruimei; Li, Ké; Li, Li; Zhang, Lili; Zheng, Huimin

doi:10.3892/etm.2019.8318

Cited by 6 publications

(6 citation statements)

References 35 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Han et al [ 144 ], the clinical importance was assessed of miR-214 and serum galectin-3 concentration in whole blood of patients with chronic heart failure. A statistically significant increase was noted of both miR-214 expression and galectin-3 serum concentration in the group with chronic heart failure.…”

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

“…A positive correlation was demonstrated between miR-214 expression and serum galectin-3 concentration, what suggested the participation of both factors in the development of chronic heart failure. Galectin-3 exerts an effect promoting the myocardial fibrosis process, while miR-214 can regulate fibroblast proliferation [ 144 ].…”

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

See 1 more Smart Citation

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

2021

View full text Add to dashboard Cite

Galectin-3 plays a prominent role in chronic inflammation and has been implicated in the development of many disease conditions, including heart disease. Galectin-3, a regulatory protein, is elevated in both acute and chronic heart failure and is involved in the inflammatory pathway after injury leading to myocardial tissue remodelling. We discussed the potential utility of galectin-3 as a diagnostic and disease severity/prognostic biomarker in different cardio/cerebrovascular diseases, such as acute ischemic stroke, acute coronary syndromes, heart failure and arrhythmogenic cardiomyopathy. Over the last decade there has been a marked increase in the understanding the role of galectin-3 in myocardial fibrosis and inflammation and as a therapeutic target for the treatment of heart failure and myocardial infarction.

show abstract

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

2021

View full text Add to dashboard Cite

show abstract

“…Second, galectin-3 levels correlate with diastolic (Ansari et al, 2018) and systolic dysfunction (Zivlas et al, 2017). Third, following treatment of heart failure, galectin-3 levels were significantly decreased (Han et al, 2020). We found that galectin-3 is significantly increased in cirrhotic rat hearts, and a galectin inhibitor, N-acetyllactosamine, significantly improved cardiac function (Yoon et al, Forthcoming 2022).…”

Section: Other Substancesmentioning

confidence: 67%

Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy

Liu

Nguyen

Yoon

et al. 2022

Front. Netw. Physiol.

View full text Add to dashboard Cite

Cardiac dysfunction associated with cirrhosis in the absence of preexisting heart disease is a condition known as cirrhotic cardiomyopathy (CCM). Cardiac abnormalities consist of enlargement of cardiac chambers, attenuated systolic and diastolic contractile responses to stress stimuli, and repolarization changes. CCM may contribute to cardiovascular morbidity and mortality after liver transplantation and other major surgeries, and also to the pathogenesis of hepatorenal syndrome. The underlying mechanisms of CCM are poorly understood and as such medical therapy is an area of unmet medical need. The present review focuses on the pathogenic mechanisms responsible for development of CCM. The two major concurrent mechanistic pathways are the inflammatory phenotype due to portal hypertension, and protein/lipid synthetic/metabolic defects due to cirrhosis and liver insufficiency. The inflammatory phenotype arises from intestinal congestion due to portal hypertension, resulting in bacteria/endotoxin translocation into the systemic circulation. The cytokine storm associated with inflammation, particularly TNFα acting via NFκB depresses cardiac function. They also stimulate two evanescent gases, nitric oxide and carbon monoxide which produce cardiodepression by cGMP. Inflammation also stimulates the endocannabinoid CB-1 pathway. These systems inhibit the stimulatory beta-adrenergic contractile pathway. The liver insufficiency of cirrhosis is associated with defective synthesis or metabolism of several substances including proteins and lipids/lipoproteins. The protein defects including titin and collagen contribute to diastolic dysfunction. Other protein abnormalities such as a switch of myosin heavy chain isoforms result in systolic dysfunction. Lipid biochemical changes at the cardiac sarcolemmal plasma membrane result in increased cholesterol:phospholipid ratio and decreased membrane fluidity. Final common pathway changes involve abnormal cardiomyocyte intracellular ion kinetics, particularly calcium. In conclusion, cirrhotic cardiomyopathy is caused by two pathways of cellular and molecular dysfunction/damage due to hepatic insufficiency and portal hypertension.

show abstract

“…In addition, one of the studies collected blood from two different locations from the same patients (vein and coronary sinus); 24% of studies used TaqMan assay to measure expression levels of miRNAs; 42% and 29% of studies were conducted in China and Europe between 2010 and 2021, respectively ( Table 1 and online supplementary Table Appendix S1 ). 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 …”

Section: Resultsmentioning

confidence: 99%

Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta‐analysis

Hosseinpour

Moradi

Devaux

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

Aim Chronic heart failure (CHF) can be classified as heart failure with preserved ejection fraction (HFpEF) or with reduced ejection fraction (HFrEF). Currently, there is an unmet need for a minimally invasive diagnostic tool for different forms of CHF. We aimed to investigate the diagnostic potential of circulating microRNAs (miRNAs) for the detection of different CHF forms via a systematic review and meta‐analysis approach. Methods and results Comprehensive search on Medline, Web of Science, Scopus, and EMBASE identified 45 relevant studies which were used for qualitative assessment. Out of these, 29 studies were used for qualitative and quantitative assessment and allowed to identify a miRNA panel able to detect HFrEF and HFpEF with areas under the curve (AUC) of 0.86 and 0.79, respectively. A panel of eight miRNAs (hsa‐miR‐18b‐3p, hsa‐miR‐21‐5p, hsa‐miR‐22‐3p, hsa‐miR‐92b‐3p, hsa‐miR‐129‐5p, hsa‐miR‐320a‐5p, hsa‐miR‐423‐5p, and hsa‐miR‐675‐5p) detected HFrEF cases with a sensitivity of 0.85, specificity of 0.88 and AUC of 0.91. A panel of seven miRNAs (hsa‐miR‐19b‐3p, hsa‐miR‐30c‐5p, hsa‐miR‐206, hsa‐miR‐221‐3p, hsa‐miR‐328‐5p, hsa‐miR‐375‐3p, and hsa‐miR‐424‐5p) identified HFpEF cases with a sensitivity of 0.82 and a specificity of 0.61. Conclusions Although conventional biomarkers (N‐terminal pro‐B‐type natriuretic peptide and B‐type natriuretic peptide) presented a better performance in detecting CHF patients, the results presented here pointed towards specific miRNA panels with potential additive values to circulating natriuretic peptides in the diagnosis of different classes of CHF. Equally important, miRNAs alone showed a reasonable capacity for ‘ruling out’ patients with HFrEF or HFpEF. Additional studies with large populations are required to confirm the diagnostic potential of miRNAs for sub‐classes of CHF.

show abstract

Expression of microRNA‑214 and galectin‑3 in peripheral blood of patients with chronic heart failure and its clinical significance

Cited by 6 publications

References 35 publications

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy

Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta‐analysis

Contact Info

Product

Resources

About